Description:
Many therapeutic progresses have been made in recent years in the field of indolent lymphoma. Beside different classical cytotoxic agents, immunotherapies have continued to develop, with new agents and new combinations recently approved. Several kinase inhibitors have been evaluated in follicular and marginal zone lymphomas, and are now available for patients, and other forms of targeted therapies are currently being investigated. All of these approaches may have specific side effects, potentially impairing patient quality of life. While these diseases are often chronic, patients overall survival has been significantly improved in the last 20 years and some of them may enjoy long periods without any treatment, and eventually be considered as cured. Others present with difficult to treat disease, refractory to multiple therapies, and histologic transformation has been usually considered as a turning point in the disease history, when other therapeutic approaches need to be implemented.

Dr. Gilles Salles will review different therapeutic options currently available for the first line or subsequent progressions in patients with follicular lymphoma, and discuss how to optimize the use of the different approaches.

Dr. Pier Luigi Zinzani will discuss the different clinical presentations of marginal zone lymphoma and address their therapeutic management. He will also address how new agents or combinations developed in the field could be used for those patients.

Dr. Sonali Smith will review the current data available for patients with transformed indolent lymphoma, and discuss the respective role of cytotoxic agents, transplant and CAR-T cells in this setting.